Tissue-Specific Human Extracellular Matrix Scaffolds Promote Pancreatic Tumour Progression and Chemotherapy Resistance
Author:
Al-Akkad WalidORCID, Acedo PilarORCID, Vilia Maria-GiovannaORCID, Frenguelli Luca, Ney AlexanderORCID, Rodriguez-Hernandez Irene, Labib Peter L.ORCID, Tamburrino Domenico, Spoletini GabrieleORCID, Hall Andrew R., Canestrari Simone, Osnato AnnaORCID, Garcia-Bernardo Jose, Sejour Leinal, Vassileva VesselaORCID, Vlachos Ioannis S., Fusai Giuseppe, Luong Tu VinhORCID, Whittaker Steven R.ORCID, Pereira Stephen P.ORCID, Vallier Ludovic, Pinzani Massimo, Rombouts KristaORCID, Mazza Giuseppe
Abstract
Over 80% of patients with pancreatic ductal adenocarcinoma (PDAC) are diagnosed at a late stage and are locally advanced or with concurrent metastases. The aggressive phenotype and relative chemo- and radiotherapeutic resistance of PDAC is thought to be mediated largely by its prominent stroma, which is supported by an extracellular matrix (ECM). Therefore, we investigated the impact of tissue-matched human ECM in driving PDAC and the role of the ECM in promoting chemotherapy resistance. Decellularized human pancreata and livers were recellularized with PANC-1 and MIA PaCa-2 (PDAC cell lines), as well as PK-1 cells (liver-derived metastatic PDAC cell line). PANC-1 cells migrated into the pancreatic scaffolds, MIA PaCa-2 cells were able to migrate into both scaffolds, whereas PK-1 cells were able to migrate into the liver scaffolds only. These differences were supported by significant deregulations in gene and protein expression between the pancreas scaffolds, liver scaffolds, and 2D culture. Moreover, these cell lines were significantly more resistant to gemcitabine and doxorubicin chemotherapy treatments in the 3D models compared to 2D cultures, even after confirmed uptake by confocal microscopy. These results suggest that tissue-specific ECM provides the preserved native cues for primary and metastatic PDAC cells necessary for a more reliable in vitro cell culture.
Funder
Fiorina Foundation and the Royal Free Charity UCL NIHR Biomedical Research Centre
Reference47 articles.
1. Pancreatic Cancer;Nat. Rev. Dis. Prim.,2016 2. Ushio, J., Kanno, A., Ikeda, E., Ando, K., Nagai, H., Miwata, T., Kawasaki, Y., Tada, Y., Yokoyama, K., and Numao, N. (2021). Pancreatic Ductal Adenocarcinoma: Epidemiology and Risk Factors. Diagnostics, 11. 3. Pergolini, I., Morales-Oyarvide, V., Mino-Kenudson, M., Honselmann, K.C., Rosenbaum, M.W., Nahar, S., Kem, M., Ferrone, C.R., Lillemoe, K.D., and Bardeesy, N. (2017). Tumour Engraftment in Patient-Derived Xenografts of Pancreatic Ductal Adenocarcinoma Is Associated with Adverse Clinicopathological Features and Poor Survival. PLoS ONE, 12. 4. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States;Cancer Res.,2014 5. Treatment and Survival of Patients with Pancreatic Ductal Adenocarcinoma: 15-Year National Cohort;BJS Open,2022
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|